Skip to main content
. Author manuscript; available in PMC: 2014 May 30.
Published in final edited form as: Cancer Cell. 2010 Apr 13;17(4):388–399. doi: 10.1016/j.ccr.2010.02.027

Figure 3. Low density lipoprotein modulate the Hh pathway inhibitory effects of itraconazole.

Figure 3

(A) High density lipoprotein (HDL) 100 µg/ml and (B) very low density lipoprotein (VLDL) 6.5 µg/ml cannot reverse Hh pathway inhibition by itraconazole. (C, D) Titration of low density lipoprotein (LDL) up to 120 µg/ml rescues either induced Hh pathway activity by ShhN ligand in Shh-Light2 cells (C) or constitutively active pathway in Ptch−/− cells (Goodrich et al., 1997; Taipale et al., 2000) (D) from the inhibitory effects of itraconazole. All signaling assays were performed in lipid depleted 10% calf serum media for Shh-Light2 cells (A–C) and 0.5% fetal bovine serum media for Ptch−/− cells. Data are mean of triplicates ± s.d.